The analgesic efficacy and safety of Butorphanol Tartrate-soaked nasal packing after nasal endoscopic surgery: a double-blind, randomized controlled trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000028880

Enrollment

Unknown

Registered

2020-01-05

Start date

2020-01-15

Completion date

Unknown

Last updated

2022-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nasal disease

Interventions

B1:Butorphanol 0.03mg kg-1

B2:Butorphanol 0.04mg kg-1

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria:patients who plan to undergo bilateral endoscopic nasal surgery ,aged between 18 and 65 years, body mass index (BMI) ranged from 18 to 30kg/m2 and American Society of Anesthesiologists grade I or II.

Exclusion criteria

Exclusion criteria: Severe central nervous system disease or definite mental disorder,sleep apnea syndrome or severe insomnia or anxiety,recent use of sedatives, analgesics, antidepressants, and anticoagulants,a history of alcohol and drug abuse,allergic to opioids or prepared narcotic drugs,serious adverse reactions occurred during the operation, illiteracy, severe visual or auditory impairment or inability to cooperate, and refusal to sign informed consent.

Design outcomes

Primary

Measure	Time frame
pain;	—

Secondary

Measure	Time frame
sleep quality;	—

Countries

China

Contacts

Public ContactShaohui Zhuang

The First Affiliated Hospital of Shantou University Medical College

doctorzsh@163.com+86 13502950710

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026